RSV lacking NS2 (rA2ΔNS2) was tested in clinical trials as a vaccine for the elderly since it was less attenuated in chimpanzees than cpts 248/404. It was shown to be over-attenuated in adults but under-attenuated in children, a contraindication for testing in infants [37]. Subunit and other synthetic vaccines have shown only moderate immunogenicity in clinical trials, even with the development

of newer adjuvant regimens. Vectored vaccines expressing RSV F and/or G have been generated based on paramyxoviruses such as Sendai virus (SeV), Newcastle disease virus (NDV), and a chimeric recombinant bovine parainfluenza virus 3 (PIV3) expressing human PIV3 F/HN and RSV-F (MEDI-534). Sendai virus expressing RSV-F or G protected the lower respiratory tract (LRT) of cotton rats against RSV infection SB203580 mw [38] and [39]. SeV-RSV-F also conferred LRT protection in African green monkeys [40]. Immunization of mice with NDV expressing www.selleckchem.com/products/AZD2281(Olaparib).html RSV-F was only modestly effective,

reducing RSV burden in lungs by approximately 1 log10 [41]. MEDI-534 was attenuated and safe in clinical trials, but it was only minimally immunogenic in adults and children [42]. Furthermore, the vaccine candidate genome was unstable, with mutations observed in vivo and in vitro [43] and [44]. Thus, while many RSV vaccine candidates have been researched extensively, an important public health gap remains for RSV disease prevention. This work

demonstrated that PIV5-based RSV vaccine candidates provide a promising alternative for RSV vaccine development. Single-dose immunization with rPIV5-RSV-F or rPIV5-RSV-G induced potent immunity against RSV challenge in mice. Importantly, the recombinant vaccine viruses did not exacerbate lung lesions relative to the RSV A2-immunized controls. Natural infection with RSV does not lead to enhanced disease upon reinfection, in contrast to immunization with formalin-inactivated RSV [45]. Inflammation in the lung tissue of mice immunized with the vaccine candidates was likely due to the induction of host immunity in response to RSV Org 27569 challenge. Serum neutralizing antibodies were generated in rPIV5-RSV-F-immunized mice, suggesting that the vaccine candidate induces a functional, systemic humoral response against RSV. Immunization with rPIV5-RSV-G did not generate neutralizing antibodies, but reduced viral burden in the lungs. The mechanism is unclear, but rPIV5-RSV-G immunization may generate protective antibodies that are non-neutralizing in vitro. In the case of the RSV-G subunit vaccine candidate, BBG2Na, passively transferred serum from immunized mice reduced lung viral burden in recipient mice at dilutions negative for neutralizing activity [46].